A premier global biopharmaceutical innovator delivering breakthrough oncology, immunology, and neuroscience therapies with robust revenue expansion and a dominant market position in obesity treatment.
Investors should consider this stock due to its unprecedented revenue growth driven by the dual blockbuster status of Alzheimer's and obesity drugs which command premium pricing. The company's ability to convert high operating profit into massive cash flow supports a robust shareholder return program, evidenced by consistent dividend growth and buybacks. As the global population ages and demand for weight-loss therapies explodes, Eli Lilly is uniquely positioned to capture significant market share with its established manufacturing scale.
Valuation premiums may be excessive given the potential for regulatory headwinds or delays in launching next-generation therapies from smaller competitors. Heavy reliance on a narrow set of high-value drugs creates concentration risk if any single product faces safety issues or patent challenges. The substantial cash flow from investing activities of -$10.97B suggests heavy capital deployment, which could be scrutinized if returns on these investments do not match the company's high cost of capital.
Eli Lilly & Co is a global biopharmaceutical leader specializing in the discovery, development, manufacturing, and marketing of innovative medicines primarily for oncology, immunology, and neuroscience. The company serves markets across North America, Europe, Asia, and Latin America with blockbuster therapies such as donanemab for Alzheimer's disease and semaglutide-based treatments for diabetes and obesity. Its financial profile reflects strong revenue growth driven by high-demand therapeutic areas and successful product launches that have significantly outpaced inflation.
Recent financial performance highlights a dramatic acceleration in profitability, with net income jumping from $5.24B in 2023 to $10.59B in 2024 and reaching $20.64B in the most recent year. Revenue surged from $28.54B in 2022 to $65.18B in the latest period, reflecting the successful commercialization of high-value therapies and a strategic pivot toward specialty pharmaceuticals. Operating cash flow of $16.81B demonstrates strong liquidity generation, enabling significant share repurchases of $4.11B and dividends of $5.38B while funding substantial investments in capital expenditures.
The global biopharmaceutical industry is characterized by intense R&D competition and rapid technological advancement in gene therapy and biologics manufacturing. Companies are increasingly focused on chronic disease management areas like oncology and metabolic disorders where recurring revenue models are viable. Regulatory bodies worldwide are tightening approval processes for novel therapies, requiring sponsors to demonstrate long-term efficacy and safety profiles before market entry.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $28.54B | $34.12B | $45.04B | $65.18B |
| Cost of Revenue | $6.63B | $7.08B | $8.42B | $11.05B |
| Gross Profit | $21.91B | $27.04B | $36.62B | $54.13B |
| Operating Expenses | $15.11B | $20.49B | $23.94B | $28.40B |
| Operating Income | $6.81B | $6.55B | $12.68B | $25.73B |
| R&D | $7.19B | — | — | — |
| G&A | $6.44B | $7.40B | $8.59B | $11.09B |
| Stock-Based Comp | $371.1M | $628.5M | $645.6M | $626.0M |
| D&A | $1.52B | $1.53B | $1.77B | $2.00B |
| Depreciation | $816.6M | $901.9M | $1.06B | $1.31B |
| Amortization | $579.7M | $505.6M | $552.9M | $488.0M |
| Other OpEx | $1.47B | $13.08B | $15.35B | $17.30B |
| Non-Operating Income | $0 | $0 | $0 | $0 |
| Interest Expense | $331.6M | $485.9M | — | — |
| Interest Income | $62.8M | $173.6M | $175.2M | — |
| Pre-Tax Income | $6.81B | $6.55B | $12.68B | $25.73B |
| Income Tax | $561.6M | $1.31B | $2.09B | $5.09B |
| Continuing Ops | $6.24B | $5.24B | $10.59B | $20.64B |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $6.24B | $5.24B | $10.59B | $20.64B |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $6.24B | $5.24B | $10.59B | $20.64B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $18.03B | $25.73B | $32.74B | $55.63B |
| Cash & Equivalents | $2.07B | $2.82B | $3.27B | $7.27B |
| Marketable Securities | $144.8M | $109.1M | $154.8M | — |
| Accounts Receivable | $6.90B | $9.09B | $11.01B | $17.76B |
| Inventory | $4.31B | $5.77B | $7.59B | $13.74B |
| Prepaid Expenses | $2.95B | — | — | — |
| Other Current Assets | $1.66B | $7.94B | $10.72B | $16.86B |
| Long-Term Assets | $31.46B | $38.28B | $45.98B | $56.85B |
| PP&E (Net) | $10.14B | $12.91B | $17.10B | $24.68B |
| Intangibles | $7.21B | $6.91B | $6.17B | $6.52B |
| Goodwill | $4.07B | $4.94B | $5.77B | $5.90B |
| Operating Leases | — | — | $1.05B | $1.26B |
| LT Investments | $2.90B | $3.05B | $3.22B | $2.80B |
| Other LT Assets | $7.13B | $10.47B | $12.67B | $15.69B |
| Total Assets | $49.49B | $64.01B | $78.71B | $112.48B |
| Current Liabilities | $17.14B | $27.29B | $28.38B | $35.23B |
| Accounts Payable | $1.93B | $2.60B | $3.23B | $5.38B |
| Current Leases | — | — | $175.7M | $222.0M |
| Other Current Liab | $14.19B | $23.53B | $23.63B | $29.63B |
| Long-Term Liabilities | $21.58B | $25.85B | $36.07B | $50.71B |
| Long-Term Debt | $14.74B | $18.32B | $28.53B | $40.87B |
| LT Operating Leases | — | — | $970.9M | $1.14B |
| Other LT Liab | $1.63B | $-2.51B | $-1.83B | $2.83B |
| Total Liabilities | $38.71B | $53.14B | $64.44B | $85.94B |
| Shareholders' Equity | $10.78B | $10.86B | $14.27B | $26.54B |
| Retained Earnings | $10.04B | $10.31B | $13.54B | $24.47B |
| AOCI | $-3.84B | $-4.33B | $-4.32B | $-2.88B |
| Total L&E | $49.49B | $64.01B | $78.71B | $112.48B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $6.24B | $5.24B | $10.59B | $20.64B |
| Non-Cash Adjustments | $-4.72B | $-14.95B | $-15.06B | $-38.30B |
| Working Capital Changes | $5.56B | $13.94B | $13.29B | $34.47B |
| Cash from Operations | $7.08B | $4.24B | $8.82B | $16.81B |
| Cash from Investing | $-3.26B | $-7.15B | $-9.30B | $-10.97B |
| Debt Issuances | $0 | $3.96B | $11.42B | $13.17B |
| Debt Repayments | $1.56B | $0 | $664.2M | $778.0M |
| Share Buybacks | $1.50B | $750.0M | $2.50B | $4.11B |
| Dividends Paid | $3.54B | $4.07B | $4.68B | $5.38B |
| Cash from Financing | $-5.41B | $3.50B | $1.23B | $-2.21B |
| FX Effect | $-167.6M | $168.6M | $-296.7M | $372.0M |
| Net Change in Cash | $-1.75B | $751.6M | $449.8M | $4.00B |
| Beginning Cash | $3.82B | $2.07B | $2.82B | $3.27B |
| Ending Cash | $2.07B | $2.82B | $3.27B | $7.27B |
The company's revenue is driven by its Pharmaceutical segment, which accounts for the vast majority of total sales through patented small molecules and biologics. Key therapeutic pillars include Oncology (e.g., Herceptin), Immunology (e.g., Xolair), Neuroscience (e.g., Trulance, donanemab), and Endocrinology/Metabolism (e.g., Mounjaro, Zepbound). The data indicates a significant shift in revenue composition toward high-margin specialty drugs rather than generic pharmaceuticals.
Regulatory uncertainties and potential delays in FDA approvals for new drug candidates could disrupt the growth trajectory of the pipeline. Intense competition from other biotech firms targeting similar indications, particularly in obesity and Alzheimer's, may pressure market share or pricing power over time. Supply chain constraints regarding specialized raw materials for insulin and GLP-1 analogs pose risks to meeting surging global demand. Patent cliffs on key assets could lead to generic erosion if new launches do not offset lost revenue.
Eli Lilly possesses deep proprietary pipelines with multiple FDA-approved blockbuster drugs that provide sustainable pricing power and high gross margins. The company benefits from an extensive global manufacturing network capable of scaling production for complex biologics like GLP-1 agonists, securing supply in a shortage-prone market. Its strong balance sheet allows for significant R&D investment, fostering a continuous innovation cycle that keeps it ahead of competitors in neurodegenerative disease treatments.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.